Mergers and Acquisitions

* On June 28, 2013, Fresenius has sold Fresenius Biotech to the Fuhrer family, owners of Neopharm, Israel’s second-largest pharmaceutical company. The transaction was closed June 28 and includes both products Removab® and ATG-Fresenius S. In December 2012, Fresenius had announced to focus on its four established business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, which offer significant growth opportunities.

This acquisition is part of Neopharm's strategic objective to the Group into a multinational fully-integrated bio-pharmaceutical company. Neopharm's objective is to establish Fresenius Biotech as an independent, rapidly-growing, innovative global player. The parties agreed not to disclose financial details of the transaction. The sale of Fresenius Biotech will have a positive effect on Fresenius earnings starting July 2013.